{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:08:22Z","timestamp":1771967302715,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,4]]},"abstract":"\n Objectives<\/jats:title>\n To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX\u2010A) injections for overactive bladder.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n This single\u2010centre, randomised, double\u2010blind, placebo\u2010controlled two period crossover trial was conducted on women scheduled for BTX\u2010A injections at our outpatient urogynaecology clinic between September 2022 and May 2024. Patients were randomly assigned (1:1) to receive either alkalinised lidocaine or placebo during the first treatment period. Alkalinised lidocaine solution comprised lidocaine hydrochloride (20\u2009mg\/mL, 20\u2009mL), sodium hydrogen carbonate (1\u2009mmoL\/mL, 10\u2009mL), and sodium chloride (9\u2009g\/L, 10\u2009mL). The matching placebo was sodium chloride (9\u2009g\/L, 40\u2009mL). The primary outcome measure was procedural pain rated on a 100\u2010mm visual analogue scale (VAS). Secondary outcomes included adverse effects such as post\u2010void residual urine volumes requiring catheterisation, urinary tract infection, haematuria 1\u2009week after treatment, and patient satisfaction measured on a 5\u2010point scale. During the second treatment period, patients received the alternative intervention.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We enrolled 50 patients, of which 41 were eligible for per\u2010protocol analyses. The mean VAS score was significantly lower following intravesical alkalinised lidocaine (mean 21.3\u2009mm, 95% confidence interval [CI] 14.7\u201327.8\u2009mm) compared to placebo (mean 41.6\u2009mm, 95% CI 35.0\u201348.1\u2009mm) with a mean difference of \u221220.3\u2009mm (95% CI \u221229.2 to \u221211.5\u2009mm;\n P<\/jats:italic>\n \u2009<\u20090.001). Adverse events and patient satisfaction did not significantly differ between the alkalinised lidocaine and placebo treatments (\n P<\/jats:italic>\n \u2009=\u20090.825 and\n P<\/jats:italic>\n \u2009=\u20090.138, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Intravesical instillation of alkalinised lidocaine before BTX\u2010A injections significantly reduced VAS pain scores compared to placebo (\n ClinicalTrials.gov<\/jats:ext-link>\n identifier: NCT05415865).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.16647","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T06:55:42Z","timestamp":1736578542000},"page":"638-647","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alkalinised lidocaine as an anaesthetic before\n onabotulinumtoxinA<\/scp>\n injections. a randomised trial"],"prefix":"10.1111","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-7953","authenticated-orcid":false,"given":"Meryam","family":"El Issaoui","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Herlev and Gentofte University Hospital Herlev Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Elmelund","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics Amager and Hvidovre Hospital Hvidovre Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Klarskov","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Herlev and Gentofte University Hospital Herlev Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642631"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25061"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.03.146"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00508\u2010024\u201002412\u20107"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2019.10.002"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66238-6"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08162.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24519"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22750"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4378"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aew466"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-138"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/0470854596"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2020-101670"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-023-05685-0"},{"key":"e_1_2_10_18_1","unstructured":"Danish Medicines Agency.Summary of product characteristics: lidocaine SAD solution for injection 2024. Available at:https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fspcweb.produktresume.dk%2FSPCREPL%2FHuman%2FL%2FLidokain%2520SAD%2C%2520injektionsv%25c3%25a6ske%2C%2520opl%25c3%25b8sning%25205%2520mg\u2010ml%2C%252010%2520mg\u2010ml%2520og%252020%2520mg\u2010ml.doc&wdOr. Accessed July 2024"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-023-05579-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2006.00936.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2015.01.021"},{"key":"e_1_2_10_22_1","first-page":"276","article-title":"On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications","volume":"109","author":"Wellek S","year":"2012","journal-title":"Dtsch Arztebl Int"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:10:58Z","timestamp":1761750658000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/bju.16647"],"URL":"https:\/\/doi.org\/10.1111\/bju.16647","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"2025-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}